JP2005530493A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530493A5
JP2005530493A5 JP2003585746A JP2003585746A JP2005530493A5 JP 2005530493 A5 JP2005530493 A5 JP 2005530493A5 JP 2003585746 A JP2003585746 A JP 2003585746A JP 2003585746 A JP2003585746 A JP 2003585746A JP 2005530493 A5 JP2005530493 A5 JP 2005530493A5
Authority
JP
Japan
Prior art keywords
polypeptide
vaccine
adjuvant
antigen
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530493A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/002207 external-priority patent/WO2003088995A2/en
Publication of JP2005530493A publication Critical patent/JP2005530493A/ja
Publication of JP2005530493A5 publication Critical patent/JP2005530493A5/ja
Pending legal-status Critical Current

Links

JP2003585746A 2002-04-22 2003-04-22 ムチン融合ポリペプチドワクチン、組成物およびそれらの使用方法 Pending JP2005530493A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37509502P 2002-04-22 2002-04-22
PCT/IB2003/002207 WO2003088995A2 (en) 2002-04-22 2003-04-22 Mucin fusion polypeptide vaccines, compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2005530493A JP2005530493A (ja) 2005-10-13
JP2005530493A5 true JP2005530493A5 (cg-RX-API-DMAC10.html) 2006-06-15

Family

ID=29251230

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585746A Pending JP2005530493A (ja) 2002-04-22 2003-04-22 ムチン融合ポリペプチドワクチン、組成物およびそれらの使用方法

Country Status (8)

Country Link
US (2) US8034351B2 (cg-RX-API-DMAC10.html)
EP (1) EP1517700B1 (cg-RX-API-DMAC10.html)
JP (1) JP2005530493A (cg-RX-API-DMAC10.html)
AT (1) ATE551069T1 (cg-RX-API-DMAC10.html)
AU (1) AU2003228067B2 (cg-RX-API-DMAC10.html)
CA (1) CA2483473A1 (cg-RX-API-DMAC10.html)
ES (1) ES2385032T3 (cg-RX-API-DMAC10.html)
WO (1) WO2003088995A2 (cg-RX-API-DMAC10.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058450A2 (en) 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
WO2003089450A2 (en) * 2002-04-22 2003-10-30 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
JP4549666B2 (ja) * 2003-12-12 2010-09-22 タカラバイオ株式会社 抗体の製造方法
US7807636B1 (en) 2004-11-12 2010-10-05 Wisconsin Alumni Research Foundation Bovine P-selectin glycorpotein ligand-1
EP1848804B1 (en) 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
FR2886298A1 (fr) * 2005-05-24 2006-12-01 Ifremer Anticorps ou fragment d'anticorps couple a un agent immunogene
WO2007087420A2 (en) * 2006-01-23 2007-08-02 Recopharma Ab Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof
WO2007132355A2 (en) * 2006-01-26 2007-11-22 Recopharma Ab Compositions and methods for inhibiting viral adhesion
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
US9662383B2 (en) * 2007-03-26 2017-05-30 University Of Massachusetts Compositions and methods for increasing immunogenicity of glycoprotein vaccines
WO2009136298A2 (en) * 2008-05-09 2009-11-12 Recopharma Ab Compositions and methods for inhibiting shiga toxin and shiga-like toxin
MX2010013059A (es) 2008-05-30 2010-12-20 Glycofi Inc Cepa de levadura para la produccion de proteinas con galactosa alfa-1,3-enlazada terminal.
CN103501804A (zh) * 2010-12-21 2014-01-08 雷科制药公司 眼泪替代物
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
CN104800838B (zh) * 2015-04-14 2018-01-09 深圳市中联生物科技开发有限公司 MUC1‑Fc多肽疫苗及其制备方法和应用
JP6441167B2 (ja) * 2015-05-15 2018-12-19 愛三工業株式会社 蒸発燃料処理装置
WO2019031938A2 (ko) 2017-08-10 2019-02-14 주식회사 굳티셀 암 치료를 위한 t 세포의 활성화 방법
WO2022204267A1 (en) 2021-03-24 2022-09-29 Alkermes, Inc. Upar antibodies and fusion proteins with the same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4710761A (en) 1985-07-09 1987-12-01 American Telephone And Telegraph Company, At&T Bell Laboratories Window border generation in a bitmapped graphics workstation
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE69019609T2 (de) * 1989-07-07 1995-11-30 Takeda Chemical Industries Ltd Proteine und deren Herstellung.
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
KR950703640A (ko) 1992-10-09 1995-09-20 가일 케이,나우톤. 간 보존 세포(liver reserve cells)
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
AU2158995A (en) * 1994-03-15 1995-10-03 Medical College Of Pennsylvania And Hahnemann University Compositions and methods for vaccines comprising alpha-galactosyl epitopes
AUPN568095A0 (en) * 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US6090381A (en) * 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
SE9701127D0 (sv) * 1997-03-26 1997-03-26 Karolinska Innovations Ab Antigenic fusionprotein carrying GALal, 3GAL epitopes

Similar Documents

Publication Publication Date Title
US6177256B1 (en) Antigen carbohydrate compounds and their use in immunotherapy
CA2347411A1 (en) Virus-like particles for the induction of autoantibodies
EP0245078B1 (en) Enhancement of antigen immunogenicity
DK2406289T3 (en) ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES
CN106432493B (zh) 抗-cd40抗体及其用途
US5194254A (en) Enhancement of antigen immunogenicity
US8114405B2 (en) Cancer vaccine based on brother of regulator of imprinted sites molecule (BORIS)
US20120121592A1 (en) Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
JP2007501602A5 (cg-RX-API-DMAC10.html)
JP2005537800A5 (cg-RX-API-DMAC10.html)
JP2021524270A5 (cg-RX-API-DMAC10.html)
JP2021524275A5 (cg-RX-API-DMAC10.html)
TW201713692A (zh) 結合lag3之抗體治療劑
WO2013016675A1 (en) Dendritic cell (dc)-vaccine therapy for pancreatic cancer
JP2010505830A5 (cg-RX-API-DMAC10.html)
CN1893925B (zh) 树突细胞的体内靶向
CA2627376A1 (en) Immunogenic compositions and methods of use
US7700737B2 (en) Therapeutic and diagnostic anti-Hsp70 antibodies
Liu et al. Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines
JP2025081549A5 (cg-RX-API-DMAC10.html)
ES2366552T3 (es) Síntesis enzimática a gran escala de glicoconjugados de mucina y sus aplicaciones en inmunología.
ES2322212T3 (es) Composicion de antigeno y linea celular que lleva el receptor manosa.
JP2019526244A5 (cg-RX-API-DMAC10.html)
US20190367568A1 (en) Calreticulin and fusion proteins
JP2002544172A5 (cg-RX-API-DMAC10.html)